4-Methylmethylphenidate

Source: Wikipedia, the free encyclopedia.
4-Methylmethylphenidate
Legal status
Legal status
Identifiers
  • methyl (2R)-2-(4-methylphenyl)-2-[(2R)-piperidin-2-yl]acetate
JSmol)
  • Cc2ccc(cc2)C(C(=O)OC)C1CCCCN1
  • InChI=1S/C15H21NO2/c1-11-6-8-12(9-7-11)14(15(17)18-2)13-5-3-4-10-16-13/h6-9,13-14,16H,3-5,10H2,1-2H3/t13-,14-/m0/s1 checkY
  • Key:WJZNCJIOIACDBR-KBPBESRZSA-N checkY
  (verify)

threo-4-Methylmethylphenidate (4-MeTMP) is a

nocaine).[1] On the other hand, several other simple ring-substituted derivatives of threo-methylphenidate such as the 4-fluoro and 3-chloro compounds are more potent than methylphenidate both in efficacy as dopamine reuptake inhibitors and in animal drug discrimination assays.[2][3][4]

4-Fluoromethylphenidate (4F-MPH) and 3-chloromethylphenidate (3-CTMP)

Legality

4-Methylmethylphenidate was banned in the UK as a

Temporary Class Drug from June 2015 following its unapproved sale as a designer drug.[5][6][7]

In the United States, 4-methylmethylphenidate may be considered illegal if intended for human consumption under the

federal analogue act
as a structural analog of methylphenidate.

In the United States, on September 22, 2023, the DEA filed a proposed rule for placement of ethylphenidate into Schedule I status, which would include its isomers. 4-Methylmethylphenidate is a positional isomer of ethylphenidate and thus the scheduling of ethylphenidate into Schedule I status would cause 4-methylmethylphenidate to be a Schedule I substance as well.[8]

See also

References